ImpediMed is a medical technology company that develops and manufactures bioimpedance spectroscopy (BIS) devices for the clinical assessment of lymphedema.

ImpediMed

ImpediMed Limited

ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.

ImpediMed Limited is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor.  ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals in the clinical assessment of secondary lymphoedema of the arm and leg in female and male cancer patients.

Government of United States of America

Versant Ventures

Starfish Ventures

While breast cancer treatments save lives, they can lead to lymphedema in up to 20% of patients. Dr. Steven Chen, our CMO, discusses on MedPage Today's KevinMD.com how early detection and innovative strategies can significantly improve survivors' quality of life. 

Discover how technologies like bioimpedance spectroscopy (BIS) are transforming care and reducing the burden of BCRL. Learn more about proactive measures and patient education that can make a real difference. 

🔗 Read the full article: https://ow.ly/qi4L50SCu1Z 

#BreastCancerAwareness #LymphedemaPrevention #CancerSurvivorship #HealthcareInnovation

New 2024 Clinical Practice Guideline Update! 


The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship have been updated to V.1.2024. The guidelines
 continue to recommend bioimpedance spectroscopy as a key technology for survivorship care. 


Discover the latest updates and comprehensive information in the NCCN Guidelines® by visiting NCCN.org. 


Learn More about bioimpedance spectroscopy technology from ImpediMed: https://ow.ly/Xh6050Syc13

We're excited to share the Lymphatic Education & Research Network (LEARN)'s latest report on the state of lymphedema care in the U.S. This comprehensive report sheds light on current knowledge and the importance of early detection, including the role of bioimpedance spectroscopy (BIS). 

This resource is vital for healthcare professionals, advocates, and policymakers to drive awareness and improve care standards. Access the report and the Communications Toolkit to join the advocacy efforts. 

#LymphedemaAwareness #BIS #EarlyDetection #LymphaticHealth 

📢 New Article Published! The latest research in the Annals of Surgical Oncology highlights the critical importance of monitoring breast cancer patients for lymphedema for at least three years post-treatment. Early detection using bioimpedance spectroscopy (BIS) can prevent progression to chronic lymphedema, ensuring better patient outcomes. 

“Breast cancer related lymphedema can develop years after cancer treatment is concluded and can progress from the subclinical stage, where intervention is possible to reverse progression, to chronic lymphedema, where this can become a lifelong condition” says Dr. Steven Chen, co-author of the article and Chief Medical Officer, ImpediMed. 

Read more about these important findings and their implications for patient care in our latest news release: https://ow.ly/zVa650SCMVx

#LymphedemaAwareness #BreastCancerCare #EarlyDetection

Wishing everyone in the United States a joyous and safe Independence Day filled with celebration and togetherness. Enjoy the festivities and time with loved ones!

🎥 Didn’t get a chance to attend our latest webinar on “Preventing Chronic Breast Cancer-Related Lymphedema: Practical Insights for Operationalizing a Lymphedema Surveillance Program”? Now you can catch up anytime!

Join Dr. Steven Chen, Dr. Allison DiPasquale, and Dr. Manpreet Kohli as they share their expertise on early detection, clinical guidelines, and effective implementation strategies for a comprehensive Lymphedema Surveillance Program.

Stay ahead in lymphedema care and support your patients with the latest knowledge and best practices.

Watch the full webinar here: https://ow.ly/ERgL50SA176

#LymphedemaCare #BreastCancerSupport #WebinarRecording #HealthcareInnovation

COM:IMPEDIMED

ImpediMed

0.04

Last Close

0.04

01/04 02:10

Market Cap

137.57M

Beta: -

Volume Today

211.12K

Avg: -

name

homepage url

country

linkedin url

employee count

sector

industry

revenue

Description

invested in

Metrics